Class II · Moderate risk
Estradiol Valerate 50mg/Ml in Ethyl Oleate Inj Injectable
Lack of assurance of sterility
FDA Drug Recalls
18,003 recalls, newest first
Class II · Moderate risk
Estradiol Valerate 40mg/Ml in Ethyl Oleate Inj Injectable
Lack of assurance of sterility
Class II · Moderate risk
Estradiol Valerate 30mg/Ml Inj #1 in Ethyl Oleate Oil Injectable
Lack of assurance of sterility
Class II · Moderate risk
Estradiol Valerate 10mg/Ml in Ethyl Oleate 10mg/Ml Injectable
Lack of assurance of sterility
Class II · Moderate risk
Cjc-1295 4mg/Ipamorelin 4mg Vial 4mg/4mg Injectable
Lack of assurance of sterility
Class II · Moderate risk
Blue Tree Lipo Extreme
Lack of assurance of sterility
Class II · Moderate risk
Bi-Mix Papaverine 40/Phentolamine 2 Inj Injectable
Lack of assurance of sterility
Class II · Moderate risk
B Complex Inj Cmp-No B12
Lack of assurance of sterility
Class II · Moderate risk
Alprostadil 45mcg/Ml 45mcg/Ml Injectable
Lack of assurance of sterility
Class II · Moderate risk
Alprostadil 40mcg/Ml Inj 40mcg/Ml Injectable
Lack of assurance of sterility
Class II · Moderate risk
Alprostadil 32mcg/Ml 32mcg/Ml Injectable
Lack of assurance of sterility
Class II · Moderate risk
Alprostadil 30mcg/Ml Inj 30mcg/Ml Injectable
Lack of assurance of sterility
Class II · Moderate risk
Alprostadil 25mcg/Ml 25mcg/Ml Injectable
Lack of assurance of sterility
Class II · Moderate risk
Alprostadil 22mcg/Ml 22mcg/Ml Injectable
Lack of assurance of sterility
Class II · Moderate risk
Alprostadil 22.5mcg/Ml 22.5mcg/Ml Injectable
Lack of assurance of sterility
Class II · Moderate risk
(well's Lipo-Lean)inositol/Choline/B-Comp+leucine+carn+…
Lack of assurance of sterility
Class II · Moderate risk
Estradiol Valerate 20 mg/mL in Ethyl Oleate Inj. 20 mg/mL Injection in vials
Lack of assurance of sterility
Class I · High risk
Methocarbamol 500mg Tablet
Labeling: Label Error on Declared Strength; Bottles labeled as Methocarbamol 500 mg Tablets actually contain Methocarbamol 750 mg Tablets
Class II · Moderate risk
Irbesartan and Hydrochlorothiazide Tablets USP
CGMP Deviations: impurity N-nitrosoirbesartan detected in API
Class II · Moderate risk
Irbesartan and Hydrochlorothiazide Tablets USP
CGMP Deviations: impurity N-nitrosoirbesartan detected in API
Class II · Moderate risk
Irbesartan Tablets USP
CGMP Deviations: impurity N-nitrosoirbesartan detected in API
Class II · Moderate risk
Irbesartan Tablets USP
CGMP Deviations: impurity N-nitrosoirbesartan detected in API
Class II · Moderate risk
Irbesartan Tablets USP
CGMP Deviations: impurity N-nitrosoirbesartan detected in API
Class III · Low risk
AllerClear D-24 hr
Failed Moisture Limits
Class III · Low risk
Loratadine-D Extended-Release Tablets
Failed Moisture Limits